Form 4 for ERNA Ernexa Therapeutics Inc.
Accepted 2026-02-17 00:00:00 ET · period of report 2026-02-10 · accession 0001104659-26-016680 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-17 | 2026-02-10 | ERNA | Cherington Charles | 10% | P - Purchase | $0.5 | +4.00M | 6.78M | +144% | +$2.00M |
| D | 2026-02-17 | 2026-02-10 | ERNA | Cherington Charles | 10% | P - Purchase | — | +4.00M | 4.00M | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-10 | P | A | 4,000,000 | $0.5 | 6,779,440 | D | — | — | (F2) The combined purchase price in the Offering per share of Common Stock and accompanying warrant was $0.50. |
| 2 | Derivative | Warrants to Purchase Common Stock | 2026-02-10 | P | A | 4,000,000 | — | 4,000,000 | D | $0.68 · 2026-02-10 to — | 4,000,000 Common Stock | (F2) The combined purchase price in the Offering per share of Common Stock and accompanying warrant was $0.50. (F3) The warrants will expire on the earlier of (i) February 10, 2031 or (ii) the 180th calendar day following the public release by the Company of clinical trial data from the first cohort of the Phase 1 study of ERNA-101. |